Topic: Plavix
Sanofi-Aventis is again calling on Genzyme, the biotech for which the French drug maker is bidding $69 a share, to participate in at least limited due diligence or takeover discussions, the WSJ reports. Sanofi also said Genzyme shareholders should be able to ...
In 1997 the FDA approved the use of Plavix (clopidogrel bisulfate), a very expensive drug used to keep sticky blood cells called platelets, from forming life threatening clots that can block blood flow. Since the approval of Plavix, doctors have prescribed it ...
WITH THE ACQUISITION OF A rival drug maker underway and a slew of new drugs expected to hit the market in the next few years, U.S. pharmaceutical giant Bristol-Myers Squibb (ticker: BMY) is on a roll. At almost $27 a share, the ...
The New York Times' Donald G. McNeil, Jr., takes a look at the science behind the tiny insects that are currently the scourge of New York City. ". This coverage of genetic studies of the blood thinner Plavix, from theheart. Some cutting ...
Acino's generic version of French drugmaker Sanofi-Aventis' Plavix blockbuster blood thinner has captured a market share of about a quarter in Germany, the Swiss company said on Thursday. Acino's drug is a copycat version of Plavix, from Sanofi-Aventis (nyse: BMY - news ...
Genzyme today rejected the $18.5 billion takeover offer presented by French drug maker Sanofi-Aventis in a so-called " Genzyme, which has recently faced manufacturing problems, says it's not "the right time" to sell, calling Sanofi's offer an "opportunistic proposal with an unreasonable ...
LONDON -- AstraZeneca PLC doubled its share buyback program on Thursday after posting strong second quarter results and revealing that a key new drug -- its blood thinner Brilinta -- has been given a thumbs up by an advisory committee of the ...
ADELPHI, Maryland (Reuters) - AstraZeneca Plc's experimental blood thinner goes before U.S. advisers on Wednesday, facing questions over why a trial of the potential blockbuster drug failed to cut heart attacks and deaths in North American patients.Brilinta, with expected annual sales of ...
Tomorrow an FDA advisory committee will ponder ticagrelor (proposed brand name: In a review posted to the FDA's website yesterday, the agency noted that the drug didn't fare favorably against the market leader, Plavix, in North American studies. In a research note, ...
Eli Lilly (LLY) is one of the largest of the " Eli Lilly's near-term forecast is strong, as Cymbalta continues to gain approval for new indications, and the company focuses on expanding their overseas sales, where they lag competitors like Pfizer (PFE). ...
Photo Gallery
-
Plavix FDA Warning
FILE - In this July 28, 2006 file photo, blood thinner medication Plavix ...AP News - -
Bristol Myers Strategy
FILE - In this July 28, 2006 file photo, blood thinner medication Plavix ...AP News - -
Plavix Prilosec
FILE - In this July 28, 2006 file photo, blood thinner medication Plavix ...AP News -
